Beckman Coulter Life Sciences and London‑based Automata announced a strategic partnership to integrate Beckman liquid‑handling and genomic instruments into Automata’s LINQ AI‑ready automation ecosystem. The pact is accompanied by Danaher Ventures’ strategic investment and board participation as Automata closed a $45 million Series C to scale deployments and software development. The collaboration aims to enable modular, autonomous work cells that generate structured datasets suitable for agentic AI and closed‑loop experimentation. Beckman’s president Joe Fox framed the tie‑up as central to bringing agentic AI to wet labs and improving reproducibility and throughput. The deal underscores continued investor and OEM interest in lab automation platforms that combine hardware, orchestration software, and data pipelines to unlock AI‑driven discovery and increase productivity across genomics, cell biology, and assay development.